AnaptysBio (ANAB) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AnaptysBio (ANAB) has outperformed Damora Therapeutics (DMRA) over the past year, gaining 129.2% versus a gain of 12.9%. Over five years, ANAB leads with a +138.8% price change compared with -76.3% for DMRA. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.26 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | DMRA |
|---|---|---|
| Share price | $46.44 | $20.49 |
| Market cap | $1.39B | $1.26B |
| 1-day change | +1.72% | +1.24% |
| YTD return | +41.24% | -12.04% |
| 1-year return | +129.24% | +12.95% |
| 5-year return | +138.84% | -76.33% |
| Forward P/E | 9.16 | — |
| EPS (TTM) | $-0.96 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $38.33 |
| 52-week low | $20.18 | $4.95 |
| Distance from 52-week high | -35.83% | -46.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.90% | +128.84% |
| Average volume | 563.32K | 539.81K |
| Shares outstanding | 29.90M | 61.74M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed DMRA by 116.3 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ANAB vs DMRA FAQ
Which is bigger, AnaptysBio or Damora Therapeutics?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.26B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, ANAB or DMRA?
ANAB returned +129.24% over the past 12 months, compared with +12.95% for DMRA (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.